In a major announcement released today, Sernova Corporation stated that it had secured exclusive worldwide rights to patent-pending technologies developed by two leading researchers at the University Health Network (UHN) of Toronto, Canada. The license pertains to the “development of stem cells into glucose-responsive therapeutic cells for the treatment of patients with insulin-dependent diabetes.”
The market for treatment of diabetes is massive, as the Center for Disease Control (CDC) estimates that are 29 million people living with diabetes in the United States, which represents approximately 9.3% of the U.S. population.
Worldwide, 370 million people are afflicted by the disease.
If successful, a cell therapy approach to the treatment of diabetes would be revolutionary. To learn more about the announcement, see the full press release from Sernova below, printed with permission from Janet Vasquez, press contact for Sernova. [Read more…]
